CN113227080A - 2,4-二氨基嘧啶衍生物 - Google Patents

2,4-二氨基嘧啶衍生物 Download PDF

Info

Publication number
CN113227080A
CN113227080A CN201980086260.6A CN201980086260A CN113227080A CN 113227080 A CN113227080 A CN 113227080A CN 201980086260 A CN201980086260 A CN 201980086260A CN 113227080 A CN113227080 A CN 113227080A
Authority
CN
China
Prior art keywords
alkyl
halogen
heteroalkyl
cancer
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980086260.6A
Other languages
English (en)
Other versions
CN113227080B (zh
Inventor
张磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zheye Biotechnology LLC
Original Assignee
Shanghai Zheye Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zheye Biotechnology LLC filed Critical Shanghai Zheye Biotechnology LLC
Publication of CN113227080A publication Critical patent/CN113227080A/zh
Application granted granted Critical
Publication of CN113227080B publication Critical patent/CN113227080B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

本发明涉及一类2,4‑二氨基嘧啶衍生物，其药学上可接受的盐、水合物、溶剂化物或立体异构体，及其制备方法以及该类化合物单独或与其他药物联合使用在治疗具有ALK2激酶介导的病理学特征的疾病中的应用

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980086260.6A 2018-12-26 2019-12-25 2,4-二氨基嘧啶衍生物 Active CN113227080B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115946616 2018-12-26
CN201811594661.6A CN111362928A (zh) 2018-12-26 2018-12-26 2,4-二氨基嘧啶衍生物
PCT/CN2019/128246 WO2020135489A1 (zh) 2018-12-26 2019-12-25 2,4-二氨基嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN113227080A true CN113227080A (zh) 2021-08-06
CN113227080B CN113227080B (zh) 2023-08-15

Family

ID=71126370

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811594661.6A Withdrawn CN111362928A (zh) 2018-12-26 2018-12-26 2,4-二氨基嘧啶衍生物
CN201980086260.6A Active CN113227080B (zh) 2018-12-26 2019-12-25 2,4-二氨基嘧啶衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811594661.6A Withdrawn CN111362928A (zh) 2018-12-26 2018-12-26 2,4-二氨基嘧啶衍生物

Country Status (2)

Country Link
CN (2) CN111362928A (zh)
WO (1) WO2020135489A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
CN1678321A (zh) * 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
CN105308033A (zh) * 2013-03-14 2016-02-03 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183300A1 (en) * 2013-05-17 2014-11-20 Suzhou Vivotide Biotechnologies Co., Ltd. Vegfr tyrosine kinase inhibitors
CA2959347C (en) * 2014-08-25 2023-03-07 Salk Institute For Biological Studies Ulk1 inhibitors and methods using same
US10738016B2 (en) * 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
US20040063705A1 (en) * 2001-08-22 2004-04-01 Jean-Christophe Harmange Substituted pyrimidinyl derivatives and methods of use
CN1678321A (zh) * 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
CN105308033A (zh) * 2013-03-14 2016-02-03 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法

Also Published As

Publication number Publication date
CN113227080B (zh) 2023-08-15
CN111362928A (zh) 2020-07-03
WO2020135489A1 (zh) 2020-07-02

Similar Documents

Publication Publication Date Title
EP2365970B1 (en) Pyridazinones and their use as btk inhibitors
CN112955459A (zh) 双环肽配体和其用途
ES2477878T3 (es) Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas
SG183302A1 (en) Androgen receptor modulators and uses thereof
WO2020035020A1 (zh) 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP2023513854A (ja) 大環状化合物およびその使用
BR112019015256A2 (pt) composto selecionado de uma substância de fórmula 1 e um sal farmaceuticamente aceitável da mesma, e composicão farmacêutica
EP3596084A1 (en) 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
CN103382206A (zh) 喹啉或喹唑啉类衍生物、其制备方法及其在医药上的应用
TWI580679B (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
TW201821427A (zh) 雙環雜芳基衍生物
JP2020511468A (ja) Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3936509A1 (en) Fgfr4 kinase inhibitor, preparation method therefor and use thereof
JP2020525469A (ja) 新規キノリノン化合物
BR112020010004A2 (pt) compostos de pirazolopiridinona
CN112778336B (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
BR112020010012A2 (pt) compostos de pirazolopiridinona
KR20170113627A (ko) S100-저해제로서 사용가능한 이미다조[2,1-b]티아졸 및 5,6-다이하이드로이미다조[2,1-b]티아졸 유도체
AU2020386189A1 (en) Adenosine receptor antagonist compounds
CA2934257C (en) Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
JP2006510727A (ja) キナーゼモジュレーター
CN113227080B (zh) 2,4-二氨基嘧啶衍生物
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
CN113227072A (zh) 2,4-二氨基嘧啶衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant